With the promise of transformative treatments, cell therapies are rising across oncology, regenerative medicine, and stem cell applications. PL BioScience supports this evolution with Human Platelet Lysate (HPL) and soon, the first artificial HPL, while expanding production in Aachen to continue to deliver this high-quality cell culture supplement worldwide.
Egetis Therapeutics AB submits rolling NDA for tiratricol
Latest NewsEgetis Therapeutics has submitted a rolling NDA for Tiratricol to treat rare MCT8 transporter deficiency. The application for priority review is based on positive ReTRIACt study results.
FoRx raises US$50m in Series A to advance PARG inhibitor
Latest NewsSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.
Belgian microbiome player MRM Health initiates R&D partnership in cancer immunotherapy
Latest NewsFollowing a €55m (US$64m) Series B financing in September, Ghent-based MRM Health today announced a strategic collaboration with the research group of Professor Emile Voest, Senior Group Leader at the Netherlands Cancer Institute (NKI) and Senior Investigator at Oncode Institute.
Biopharmaceutical sector welcomes EU Biotech Act
Latest NewsThe European Commission has unveiled the first part of its draft for a Biotech Act, focusing on health and medical biotechnology. The proposal has won strong support from industry stakeholders, who say it addresses the urgent need for faster innovation processes to retain and develop biotech in Europe.
PL BioScience: Pioneering the Future of Cell Culture
BackgroundWith the promise of transformative treatments, cell therapies are rising across oncology, regenerative medicine, and stem cell applications. PL BioScience supports this evolution with Human Platelet Lysate (HPL) and soon, the first artificial HPL, while expanding production in Aachen to continue to deliver this high-quality cell culture supplement worldwide.
Sobi strengthens gout pipeline with Arthrosi acquisition
Latest NewsSobi AB has completed the US$1.5bn acquisition of Chinese Arthrosi Therapeutics Ltd. Its lead candidate, pozdeutinurad, a URAT1 inhibitor for gout, is in pivotal global Phase-III trials, with China licensing targeting approval by 2028.
Sanofi facing tolebrutinib setback in MS
Latest NewsSanofi’s tolebrutinib fails Phase III in PPMS, while FDA postpones decision on targeted therapy approval for nrSPMS.
Eifo and Fsg back Fida Biosystems with €5m investment
Latest NewsFida Biosystems ApS has added €5m from EIFO and FSG to an ongoing Series A financing to scale its Flow-Induced Dispersion Analysis platform, advancing in-solution biophysical analysis for drug discovery.
miRNA discovery & development platform
Sponsored PublicationsPharmahungary Group (PH) developed miRNAtarget, a miRNA discovery software tool based on miRNA-mRNA molecular networks. PH holds patent families on 4 cardio-protective microRNAs families (protectomiRs) and seeks for co-development partners and/or early stage investors. PH also offers its miRNA discovery and development service platform that includes efficacy testing from in vitro to large animal models in various therapeutic areas.
Europe’s moment: We could be the heroes of biotech
OpinionCapital is tight and patience is being tested. Yet Europe’s life sciences sector continues to deliver. Innovation doesn’t stop when markets turn; it adapts and matures.